Insights from
UBC's Expert Voices

Modern medical record retrieval is transforming real-world evidence. Datavant’s approach combines nationwide reach, deep data connectivity, and high record yields to deliver comprehensive, research-ready datasets.

UBC attended the 2025 NORD Rare Diseases & Orphan Products Breakthrough Summit, where patient voices, scientific innovation, and regulatory expertise converged to shape the future of rare-disease research. Learn what inspired us and how we’re advancing real-world evidence, patient partnerships, and innovative trial designs to accelerate progress for the rare-disease community.

As cell and gene therapies reshape treatment paradigms, patient support programs must evolve to meet new challenges. Discover how strategic alignment, payer advocacy, and innovative solutions can optimize the patient journey.

UBC recently completed a multi-country feasibility assessment to identify disease registries capable of supporting a PASS for a novel therapy targeting a hereditary muscular disorder. The study evaluated registry data elements, quality, and governance to ensure fit-for-purpose real-world data (RWD) for generating reliable RWE.

Learn how companies are making the most of their oversight capabilities by leveraging real-time data to improve the health of their pharmacovigilance program.

AI is revolutionizing drug safety, but without proper guardrails, it can introduce new risks. Learn how risk-based integration strategies are helping life sciences companies harness AI’s power while maintaining trust, transparency, and compliance.

Platforms designed specifically for the collection and communication of operational pharmacovigilance data are breaking down long-standing barriers to real-time PV oversight.

Drug repurposing is transforming the landscape of rare disease treatment by leveraging existing medications for new uses. With significantly lower development costs and faster timelines, this approach is gaining traction—especially when supported by natural history studies that provide deep insights into disease progression and real-world treatment patterns.

The EMA’s August 2025 guidance on embryo-foetal risk minimisation marks a pivotal step in harmonizing safety protocols across the EU. This blog breaks down the new Addendum I to GVP Module XVI, clarifying what constitutes a Pregnancy Prevention Programme and how risk minimisation tools can be effectively implemented without compromising patient access to essential treatments.